Company says treatment shows strong efficacy and convenient dosing profile

Specialist group to review preclinical and clinical proposals ahead of funding decision

European Commission authorises therapy for children and adults with early‑onset disease

Phase 3 studies report meaningful reductions in exacerbations across broad patient groups

CHMP decision allows self‑administration from phase 5 for people with multiple myeloma

Laigo Bio has completed the second close of its seed financing round at €5.5m, bringing the total raised […]

Axplora has announced plans to build a 4,500sqm R&D and laboratory hub at its Farmabios site in Gropello […]

DNA Script has signed distribution agreements with Gencell, Bio-Medical Science (BMS) and Biostream, expanding global access to its […]

Ondine Biomedical has announced the North American phase 3 study has reached more than 93% enrolment, bringing the […]

Early trial shows more than 50% LRRK2 reduction and supports expansion into other neurodegenerative conditions